Leerink Partnrs Estimates Geron’s Q4 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN) – Analysts at Leerink Partnrs reduced their Q4 2025 earnings per share estimates for Geron in a research report issued to clients and investors on Wednesday, February 26th. Leerink Partnrs analyst F. Khurshid now forecasts that the biopharmaceutical company will post earnings of ($0.01) per share for the quarter, down from their prior estimate of $0.02. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million.

GERN has been the subject of a number of other reports. HC Wainwright cut Geron from a “buy” rating to a “neutral” rating in a research note on Wednesday. Barclays reissued an “overweight” rating on shares of Geron in a research report on Thursday. B. Riley downgraded Geron from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $3.50 to $2.00 in a research note on Thursday. Finally, Needham & Company LLC lifted their target price on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.77.

Geron Stock Performance

Shares of NASDAQ:GERN opened at $1.61 on Thursday. Geron has a 1-year low of $1.46 and a 1-year high of $5.34. The stock has a market capitalization of $973.25 million, a P/E ratio of -5.03 and a beta of 0.53. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The business has a 50-day moving average price of $3.00 and a two-hundred day moving average price of $3.81.

Institutional Trading of Geron

A number of hedge funds and other institutional investors have recently made changes to their positions in GERN. RTW Investments LP bought a new position in Geron in the third quarter valued at $200,268,000. Nvest Financial LLC bought a new position in shares of Geron in the 4th quarter valued at about $693,000. Janus Henderson Group PLC grew its holdings in shares of Geron by 140.0% in the 3rd quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company’s stock valued at $102,193,000 after acquiring an additional 13,163,889 shares in the last quarter. Barclays PLC increased its position in shares of Geron by 114.9% in the third quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company’s stock valued at $5,902,000 after acquiring an additional 694,931 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in Geron during the third quarter worth about $1,102,000. 73.71% of the stock is currently owned by institutional investors and hedge funds.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.